Patent Application
20240198119
The present disclosure relates generally to pacing therapy, and more particularly to applying anti-tachycardia pacing using a subcutaneous implantable cardioverter-defibrillator.
Heart failure (HF) is a debilitating, end-stage disease in which abnormal function of the heart leads to inadequate blood flow to fulfill the needs of the body's tissues. Typically, the heart loses propulsive power because the cardiac muscle loses capacity to stretch and contract. Often, the ventricles do not adequately fill with blood between heartbeats, and the valves regulating blood flow may develop leaks, allowing regurgitation or backflow of blood. The impairment of arterial circulation deprives vital organs of oxygen and nutrients. Fatigue, weakness, and inability to carry out daily tasks may result. Not all HF patients suffer debilitating symptoms immediately. Some may live actively for years. Yet, with few exceptions, the disease is relentlessly progressive. As HF progresses, it tends to become increasingly difficult to manage.
Heart failure may result in patients experiencing ventricular arrhythmias, such as ventricular tachycardia (VT). VT may be treated by ablation and/or pacing.
Subcutaneous implantable cardioverter-defibrillators (SICDs) are a type of implantable cardiac device (ICD) generally used in patients who do not require cardiac pacing. This pacing limitation, however, prevents a potentially large pool of patients from getting an SICD. Although it has been suggested that leadless pacemakers may be used in conjunction with SICDs to support the needs of patients who require pacing, leadless pacemakers require an additional implantation procedure and may be relatively expensive.
Accordingly, it would be desirable to provide an SICD capable of treating VT by applying pacing.
In one embodiment, the present disclosure is directed to a subcutaneous implantable cardioverter-defibrillator (SICD) implantable in a subject. The SICD includes a case including a controller, and at least one conductive lead extending from the case, the at least one conductive lead including a plurality of coil electrodes, wherein the SICD is configured, via the controller, to apply anti-tachycardia pacing (ATP) to the subject using the at least one conductive lead.
In another embodiment, the present disclosure is directed to a method of assembling a subcutaneous implantable cardioverter-defibrillator (SICD). The method includes coupling at least one conductive lead to a case, the at least one conductive lead including a plurality of coil electrodes. The method further includes installing a controller in the case, the controller configured to cause the SICD to apply anti-tachycardia pacing (ATP) to the subject using the at least one conductive lead.
The foregoing and other aspects, features, details, utilities and advantages of the present disclosure will be apparent from reading the following description and claims, and from reviewing the accompanying drawings.
Corresponding reference characters indicate corresponding parts throughout the several views of the drawings.
The systems and methods described herein facilitate treating ventricular tachycardia (VT) by applying anti-tachycardia pacing (ATP) using a subcutaneous implantable cardioverter-defibrillator (SICD). That is, as described herein, the electrodes of an SICD may be used to treat patients that experience occasional VT. In some embodiments, the electrodes of the SICD may also be used to apply high voltage (HV) therapy.
In the embodiments described herein, ATP may be performed using pulses having an amplitude corresponding to a relatively small supra-threshold margin (e.g., approximately 1.2 times the DFT) at relatively large pulse widths (e.g., from approximately 4 to 40 milliseconds (ms)). These pulses may be minimized to reduce skeletal muscle stimulation in the subject. For example, pulses in the 20 to 200 milliamp (mA) range may be driven into a 50 ohm (Ω) load using only approximately 2 to 10 volts (V).
In some embodiments, larger pacing pulses may be used to capture more of the subject's heart, which may increase the probability of a single ATP pulse (or relatively few ATP pulses) terminating VT. This facilitates treating VT without using high voltage defibrillation pulses.
In the following description, with respect to the embodiments shown in
In this embodiment, first coil electrode 108 and second coil electrode 110 are anterior of heart 101, and second conductive lead 106 wraps around a side of the patient such that fourth coil electrode 114 is posterior of heart 101. Further, first coil electrode 108 and second coil electrode 110 are oriented generally orthogonally to fourth coil electrode 114. Alternatively, the case and coils of SICD system 100 may have any suitable position and orientation. For example, in some embodiments, first coil electrode 108 is positioned closer to case 102, and second coil electrode 110 is positioned approximately where first coil electrode is shown in
In this embodiment, ATP may be achieved using first coil electrode 108, second coil electrode 110, or a combination of first coil electrode 108 and second coil electrode 110. Further, an evoked response may be detected using other combinations of the coils of SICD system 100. For example, the following Table 1 lists several example pacing vectors and paced evoked response sensing electrode combinations. The numbers listed in Table 1 correspond to the part numbers of the components.
In some embodiments, the electrode combination that provides a smallest accelerometer signal (e.g., detected using an accelerometer in case 102) is used for ATP (i.e., that combination is automatically selected by the controller). This facilitates reducing unnecessary skeletal muscle stimulation. Further, in some embodiments, SICD system 100 may automatically analyze (using the controller) which electrode combination detects the largest evoked response and automatically use this combination for evoked response detection. Further, if no evoked response is detected, the amplitude of the ATP pulses may be increased.
The following Table 2 lists several example electrode configurations for biphasic defibrillation pulse delivery with low DFT. Further, Table 2 lists corresponding electrode combinations for dual vector sensing.
Because myopotentials may be generated by skeletal muscle contraction on one vector and not the other, a cross-correlation is performed between the two sensing vectors to increase the signal to noise ratio in such situations. See, for example, U.S. Pat. Nos. 7,970,473, and 7,447,540, both of which are incorporated herein by reference in their entirety. Further, in some embodiments, sensing vectors that provide a largest R-wave and/or a largest R-wave to T-wave ratio may be automatically selected to reduce the probability of under-sensing R-waves and over-sensing T-waves.
In this embodiment, first coil electrode 208 and second coil electrode 210 are anterior of heart 101, and second conductive lead 206 wraps around a side of the patient such that fourth coil electrode 214 is posterior of heart 101. Further, first coil electrode 208 and second coil electrode 210 are oriented generally parallel to fourth coil electrode 214. Alternatively, the case and coils of SICD system 200 may have any suitable position and orientation. For example, in some embodiments, case 202 may be located in a mid-axillary position, on the left side of the subject, similar to the position of case 302 (shown in
In this embodiment, ATP may be achieved using first coil electrode 208, second coil electrode 210, or a combination of first coil electrode 208 and second coil electrode 210. Further, evoked response may be detected using other combinations of the coils of SICD system 200. For example, the following Table 3 lists several example pacing vectors and paced evoked response sensing electrode combinations. The numbers listed in Table 3 correspond to the part numbers of the components.
As with SICD system 100, in some embodiments, the electrode combination that provides a smallest accelerometer signal (e.g., detected using an accelerometer in case 202) is used for ATP. This facilitates reducing unnecessary skeletal muscle stimulation. Further, in some embodiments, SICD system 200 may automatically analyze which electrode combination detects the largest evoked response and automatically use this combination for evoked response detection. Further, if no evoked response is detected, the amplitude of the ATP pulses may be increased.
The following Table 4 lists several example electrode configurations for biphasic defibrillation pulse delivery with low DFT. Further, Table 4 lists corresponding electrode combinations for dual vector sensing.
In this embodiment, first coil electrode 308, second coil electrode 310, and third coil electrode 312 are anterior of heart 101. Further, first coil electrode 208 is oriented generally parallel to second coil electrode 310 and third coil electrode 312. Alternatively, the case and coils of SICD system 300 may have any suitable position and orientation. For example, in some embodiments, first coil electrode 308 may be segmented into two separate coils.
In this embodiment, ATP may be achieved using first coil electrode 308, second coil electrode 310, third coil electrode 312, or a combination of at least two of first coil electrode 308, second coil electrode 310, third coil electrode 312. Further, evoked response may be detected using other combinations of the coils of SICD system 300. For example, the following Table 5 lists several example pacing vectors and paced evoked response sensing electrode combinations. The numbers listed in Table 5 correspond to the part numbers of the components.
As with SICD system 100, in some embodiments, the electrode combination that provides a smallest accelerometer signal (e.g., detected using an accelerometer in case 302) is used for ATP. This facilitates reducing unnecessary skeletal muscle stimulation. Further, in some embodiments, SICD system 300 may automatically analyze which electrode combination detects the largest evoked response and automatically use this combination for evoked response detection. Further, if no evoked response is detected, the amplitude of the ATP pulses may be increased.
The following Table 6 lists several example electrode configurations for biphasic defibrillation pulse delivery with low DFT. Further, Table 6 lists corresponding electrode combinations for dual vector sensing.
When applying ATP using a SICD system (such as SICD systems 100, 200, and 300), to prevent sensing relatively large pacing pulse artifacts, a sense amplifier is blanked (i.e., prevented from sensing) just before delivery of pacing pulses. For example,
As shown in
Just prior to delivering an ATP pulse (e.g., 1 ms before delivering an ATP pulse), first input switch 410, second input switch 414, and output switch 426 are opened (e.g., using the controller). Capacitor 428 acts as a sample and hold element, retaining the measured EKG level just prior to pacing. After the pacing pulse is delivered (e.g., approximately 5 to 20 ms later), first input switch 410, second input switch 414, and output switch 426 are closed (e.g., using the controller), and sensing resumes. In this embodiment, the digitized output signal is analyzed for an evoked response by determining if the derivative of the signal exceeds a negative or positive threshold (e.g., ±0.01 mV/ms) in a predetermined time period (e.g., 175 ms after the pacing pulse).
As shown in
At block 604, is determined whether at least 3 of 4 VT events satisfy certain criteria. Alternatively, other ratios may be used (e.g., 12 of 16 events). If the cycle length is greater than 320 ms (indicating a sinus rhythm) for at least 3 of 4 events, flow proceeds to block 606, and no action is taken. If the cycle length is less than 240 ms (indicating ventricular fibrillation (VF)) for at least 3 of 4 events, flow proceeds to block 608, and a defibrillating shock is delivered. If, however, the cycle length is greater than or equal to 240 ms and less than or equal to 320 ms (indicating VT) for at least 3 of 4 events, flow proceeds to block 610, and a single ATP pulse is delivered at Z (i.e., 82%) of the cycle length following the last event.
Subsequently, at block 612, it is determined whether capture is achieved based on the evoked response and/or extension of the cycle length. If capture is achieved, flow proceeds to block 614 and subsequently to block 616, where it is determined whether Z is less than 75%. If Z is not less than 75%, flow proceeds to block 618, at which point the amplitude of subsequent ATP pulses is increased (e.g., by 20%), and Z is reduced by 6%, before flow returns to block 602. If Z is less than 75%, flow proceeds to block 622, and i) a predetermined number of ATP pulses (e.g., 4 to 5 pulses) are applied over the next cycle length at equally spaced intervals or, alternatively, ii) a predetermined number of ATP pulses (e.g., 3 to 8 pulses) are delivered at 88% of the cycle length.
At block 612, if capture is not achieved, flow proceeds to block 630 and subsequently to block 632, where it is determined whether Z is less than 100%. If Z is less than 100%, flow proceeds to block 634, at which point the amplitude of subsequent ATP pulses is increased (e.g., by 20%), and Z is increased by 6% (although keeping Z below 100%), before flow returns to block 604. If Z is not less than 100%, flow proceeds to block 622, and i) a predetermined number of ATP pulses (e.g., 4 to 5 pulses) are applied over the next cycle length at equally spaced intervals or, alternatively, ii) a predetermined number of ATP pulses (e.g., 3 to 8 pulses) are delivered at 88% of the cycle length in an attempt to achieve capture.
In the systems and methods described herein, discomfort from the applied ATP may be reduced using several techniques.
For example, in some embodiments, the amplitude of the ATP pulses can be minimized by performing capture verification using the evoked response. For example, the paced evoked response may be analyzed to perform capture verification and to determine the capture threshold (which may be, e.g., approximately 30 to 80 mA). Further, the coil electrodes may be coated with a non-polarizable coating to reduce polarization, so that immediate sensing after pacing is possible.
Further, as described above, the sense amplifier can be blanked during pacing, and a sample and hold circuit (e.g., a capacitor) can be used to hold the ECG voltage during pacing to facilitate detecting the evoked response. If the evoked response is not detected, the ATP pulse amplitude may be increased on subsequent pulses until capture is achieved and verified from the evoked response.
Further, in some embodiments, monophasic cathodic pulses are delivered instead of biphasic pulses. Monophasic cathode pulses have lower thresholds, and may be less noxious to the subject.
In addition, in some embodiments, a learning mode is implemented that is capable of recognizing a pulse regiment that is effective in achieving VT termination, and using that pulse regiment in terminate subsequent future arrhythmias. For example, if the VT has a cycle length of 300 ms, and is terminated by a 50 mA pulse at 93% of the cycle length, then the next time arrhythmia occurs, a 50 mA pulse is applied at 93% of the cycle length. Similarly, if the VT has a cycle length of 270 ms, and is terminated by a 80 mA pulse at 88% of the cycle length, then the next time arrhythmia occurs, a 80 mA pulse is applied at 88% of the cycle length.
In some embodiments, a predetermined (and programmable) number of ATP pulses are applied to attempt VT termination before shocking is implemented. Alternatively, an algorithm may be used to provide cardioversion with a predetermined number of ATP attempts.
Further, in some embodiments, an in-line pacing electrode coil may be positioned over a point of maximum impulse (e.g., a V3 lead location) or in a parasternal location. The anode that does not provide the pacing may be the case or a larger electrode than the pacing electrode. In some embodiments, the entire shocking electrode may be used to perform ATP, allowing for multisite pacing that may improve ATP efficacy in many patients. Alternatively, the shocking electrode may be divided into multiple segments, as described above. In such cases, pacing may be achieved using either segment individually or both segments combined. Further, the electrode combination that provides the lowest pacing threshold may be automatically selected using a capture verification algorithm that measures the pacing threshold. For defibrillation, the segmented pacing electrode acts as one shocking electrode. Optimizing the pacing electrode size (i.e., length) may facilitate minimizing skeletal muscle stimulation while achieving adequate length for capture. For example, each segment may have a length from approximately 3 to 6 centimeters (cm).
In addition, in some embodiments, a short coil segment is utilized for a first one or more rounds of ATP, allowing for adjustment of cycle length and/or pacing output in each consecutive ATP round. In case of failure in the first one or more rounds to terminate the VT, two or more coil segments are electrically coupled for delivering a second one or more rounds of ATP. In this scheme, the first one or more rounds elicit less skeletal muscle and/or diaphragmatic contraction, while the second one or more rounds more aggressively attempt to capture ventricular myocardium to penetrate into the VT circuit, with less regard for skeletal muscle and/or diaphragmatic contraction.
In some embodiments, a time optimization of ATP pulse delivery is controlled to coincide with spatial optimization. Spatial optimization may be controlled largely by selection of one or more stimulating electrodes. Specifically, the smaller the electrode and the closer to the myocardium, the more the electrode behaves like a point stimulator. In contrast, the larger the electrode and the further from the myocardium, the more the electrode behaves like a field stimulator. Field stimulation, at a tissue level, may result in multiple coordinated yet spatially distributed stimulation capture locations.
For example, suppose a first ATP attempt uses a single short coil segment at a low-to-moderate stimulation amplitude. This would be expected to result in a virtual point stimulation. If the first ATP attempt fails to terminate the VT, modulation of timing with regard to cycle length can be performed (e.g., as described in associated with
For example,
At block 702, after ATP is applied using a particular vector and stimulation parameters, it is determined whether the ATP was successful in terminating VT. If the ATP was successful, flow proceeds to block 704, and the vector and stimulation parameters that were used in the ATP are recorded (i.e., stored) with an indication that the vector and stimulation parameters successfully terminated VT. Then, for future episodes, the recorded vector and stimulation parameters that previously resulted in terminating VT can be retrieved, and ATP is again applied using that same vector and stimulation parameters.
If, however, at block 702, the ATP was not successful, flow proceeds to block 706, and the vector and stimulation parameters are recorded with an indication that they were unsuccessful. Then, at block 708, at least one of the vector and the stimulation parameters are modified and ATP is applied again. Flow then returns to block 702 to determine whether this ATP was successful.
Accordingly, the systems and methods described herein facilitate applying anti-tachycardia pacing ATP to treat VT using subcutaneous implantable cardioverter-defibrillators SICDs. An SICD implantable in a subject includes a case including a controller, and at least one conductive lead extending from the case. The at least one conductive lead includes a plurality of coil electrodes, wherein the SICD is configured, via the controller, to apply anti-tachycardia pacing (ATP) to the subject using the at least one conductive lead. Further, those of skill in the art will appreciate that, in some embodiments, the electrodes of the SICD (and the electrode configurations described herein) may also be used to apply high voltage (HV) therapy.
Although certain embodiments of this disclosure have been described above with a certain degree of particularity, those skilled in the art could make numerous alterations to the disclosed embodiments without departing from the spirit or scope of this disclosure. All directional references (e.g., upper, lower, upward, downward, left, right, leftward, rightward, top, bottom, above, below, vertical, horizontal, clockwise, and counterclockwise) are only used for identification purposes to aid the reader's understanding of the present disclosure, and do not create limitations, particularly as to the position, orientation, or use of the disclosure. Joinder references (e.g., attached, coupled, connected, and the like) are to be construed broadly and may include intermediate members between a connection of elements and relative movement between elements. As such, joinder references do not necessarily infer that two elements are directly connected and in fixed relation to each other. It is intended that all matter contained in the above description or shown in the accompanying drawings shall be interpreted as illustrative only and not limiting. Changes in detail or structure may be made without departing from the spirit of the disclosure as defined in the appended claims.
When introducing elements of the present disclosure or the preferred embodiment(s) thereof, the articles “a”, “an”, “the”, and “said” are intended to mean that there are one or more of the elements. The terms “comprising”, “including”, and “having” are intended to be inclusive and mean that there may be additional elements other than the listed elements.
As various changes could be made in the above constructions without departing from the scope of the disclosure, it is intended that all matter contained in the above description or shown in the accompanying drawings shall be interpreted as illustrative and not in a limiting sense.
This application is a continuation of U.S. Non-Provisional application Ser. No. 16/057,605, filed Aug. 7, 2018, which is hereby incorporated by reference in its entirety.
| Number | Date | Country | |
|---|---|---|---|
| Parent | 16057605 | Aug 2018 | US |
| Child | 18593724 | US |
